ArticleFrontiers in immunology2025
Multiomics profiling Identifies MCMBP as a prognostic biomarker and a potential immune-related target in pancreatic ductal adenocarcinoma via the JAK-STAT3 pathway.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microchromosome maintenance protein-binding protein (MCMBP) is aberrantly expressed in cancers and proposed as a diagnostic marker and therapeutic target, but its role in pancreatic ductal adenocarcinoma (PAAD) remains unclear. Methods: We performed a comprehensive analysis of MCMBP in PAAD using multi-omics data resources, including TCGA, GTEx, CPTAC, GEO, GDSC, TIDE, HPA, MethSurv, DiseaseMeth, and LinkedOmicsKB. We examined its prognostic characteristics, epigenetic alterations, immune infiltration, immunotherapy response, and drug sensitivity. By integrating transcriptomic, proteomic, and phosphoproteomic data, we explored the biological functions and pathways of MCMBP. Sensitive drugs related to MCMBP were identified through the GDSC and Connectivity Map (CMap) drug libraries, with further functional insights obtained through GO and KEGG enrichment analyses. Potential mechanisms were investigated via gene functional experiments, phos-phorylation site predictions from LinkedOmicsKB, and protein expression validation. Results: Pan-cancer analysis revealed that MCMBP overexpression correlates with poor prognosis, including in PAAD. Cox regression identified MCMBP as an independent prognostic factor for PAAD. Low DNA methylation and high m6A modification of MCMBP may promote PAAD progression and correlate with adverse prognosis. Ge-ne function and immune infiltration analyses indicated that high MCMBP expression is closely associated with immune-related pathways, tumor cell proliferation, survival, and immune cell differentiation, and may promote Treg accumulation and immune ch-eckpoint upregulation. PAAD patients with low MCMBP expression exhibited greate-r sensitivity to anti-PD-L1 immunotherapy, suggesting a potential synergistic effect o-f MCMBP expression with anti-PD-L1 treatment. High MCMBP expression was ass-ociated with sensitivity to Gemcitabine combined with Paclitaxel, as well as small mo-lecules such as Tozasertib and Motesanib. MCMBP knockdown inhibited PAAD cell proliferation, migration, invasion, and G1-S transition. Immunohistochemical results s-howed that high MCMBP expression correlated with elevated PD-L1 levels and redu-ced CD4+ T cell infiltration in PAAD, which significantly associated with poor prog-nosis. MCMBP modulated PD-L1 through activation of the JAK-STAT3 signaling pat-hway, thereby promoting PAAD progression. Conclusions: Overexpression of MCMBP may serve as a prognostic biomarker and p-otential therapeutic target in PAAD. It drives PAAD progression by activating the JAK-STAT3 pathway to upregulate PD-L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.